Skip to main content

Table 1 Clinical characteristics of DLBCL patients according to circEAF2 expression

From: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Characteristics

Low expression

High expression

P value

N = 51

N = 49

Age

  

0.8418

 ≤ 60

29 (56.9)

29 (59.2)

 

 > 60

22 (43.1)

20 (40.8)

 

Sex

  

0.6873

 Female

21 (41.2)

23 (46.9)

 

 Male

30 (58.8)

26 (53.1)

 

ECOG

  

0.0095

 0–1

22 (43.1)

34 (69.4)

 

 2–5

29 (56.9)

15 (30.6)

 

Ann-Arbor stage

  

0.0699

 I/II

18 (35.3)

27 (55.1)

 

 III/IV

33 (64.7)

22 (44.9)

 

Extranodal site

  

0.1430

 0–1

30 (58.8)

36 (73.5)

 

 ≥ 2

21 (41.2)

13 (26.5)

 

LDH

  

0.0152

 Normal

16 (31.4)

28 (57.1)

 

 Elevated

35 (68.6)

21 (42.9)

 

IPI

  

0.0029

 0–2

20 (39.2)

34 (69.4)

 

 3–5

31 (60.8)

15 (30.6)

 

Hansa

  

0.6723

 Non-GCB

32 (62.7)

33 (68.8)

 

 GCB

19 (37.3)

15 (31.3)

 

CR

  

0.0206

 No

18 (35.3)

7 (14.3)

 

 Yes

33 (64.7)

42 (85.7)

 
  1. Values are reported as N (%) of patients unless indicated otherwise
  2. CR Complete remission, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH Lactic dehydrogenase, GCB Germinal center B-cell
  3. aThe calculation was based on 97 patients with available data